---
schema_version: "secwatch.filing_event.v1"
accession: "0001854270-22-000041"
form_type: "8-K"
ticker: "SNTI"
cik: "0001854270"
company_name: "Senti Biosciences, Inc."
filed_at: "2022-11-10T23:59:59+00:00"
generated_at: "2026-06-21T23:56:25.661313+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Senti Bio reports Q3 net loss of $16.6M; cash $114.9M; SENTI-202 and SENTI-301A IND filings on track for 2023

## Summary
- Net loss $16.6M ($0.38/share) for Q3 2022; R&D expenses $8.1M, G&A $10.8M.
- Cash and equivalents $114.9M as of Sep 30, 2022; expected cash runway into 2024.
- SENTI-202 IND on track for 2023; Phase 1 trial planned for CD33/FLT3+ hematologic malignancies including AML and MDS.
- Selected SENTI-301A development candidate for GPC3+ solid tumors including HCC; IND expected in 2023.
- Preclinical data for SENTI-301A and SENTI-401 presented at SITC; SENTI-202 data to be presented at ASH Dec 2022.

## SEC filing metadata
- accession: 0001854270-22-000041
- form_type: 8-K
- ticker: SNTI
- cik: 0001854270
- company_name: Senti Biosciences, Inc.
- filed_at: 2022-11-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1854270/000185427022000041/0001854270-22-000041-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1854270/000185427022000041/snti-20221110.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001854270-22-000041
- JSON: https://secwatch.observer/filing/0001854270-22-000041.json
- Plain text: https://secwatch.observer/filing/0001854270-22-000041.txt

## Key facts
- Earnings Releases
  Senti Biosciences, Inc. reported financial results for the quarter ended September 30, 2022.
  - Period: the quarter ended September 30, 2022
  - Result: reported results
  source text: On November 10, 2022, Senti Biosciences, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1854270/000185427022000041/0001854270-22-000041-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.